{"nctId":"NCT01846299","briefTitle":"To Assess the Efficacy and Safety of Intravitreal Ranibizumab in People With Vision Loss Due to Macular Edema","startDateStruct":{"date":"2013-10"},"conditions":["Macular Edema (ME)"],"count":181,"armGroups":[{"label":"Ranibizumab","type":"EXPERIMENTAL","interventionNames":["Drug: Ranibizumab"]},{"label":"Sham control","type":"SHAM_COMPARATOR","interventionNames":["Other: Sham control"]}],"interventions":[{"name":"Sham control","otherNames":[]},{"name":"Ranibizumab","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of active ME secondary to any causes (for adult patients: except diabetic macular edema (DME), age-related macular degeneration (AMD) and retinal vein occlusion (RVO));\n* BCVA must be between ≥ 24 and ≤ 83 letters;\n* Visual loss should be mainly due to the presence of any eligible types of ME.\n\nExclusion Criteria:\n\n* Women of child-bearing potential,\n* Active malignancies;\n* History of stroke less than 6 months prior to screening;\n* Uncontrolled systemic inflammation or infection, related directly to the underlying causal disease of ME;\n* Active diabetic retinopathy, active ocular/periocular infectious disease or active severe intra-ocular inflammation;\n* Any type of advanced, severe or unstable ocular disease or its reatment;\n* ME with a high likelihood of spontaneous resolution.\n\nOther protocol-defined inclusion/exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Best-corrected Visual Acuity (BCVA) in Study Eye","description":"BCVA was assessed in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity (VA) testing charts at an initial testing distance of 4 meters. A positive change from baseline indicated improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.7","spread":"0.81"},{"groupId":"OG001","value":"2.9","spread":"0.89"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in BCVA in Study Eye up to Month 2","description":"BCVA was assessed in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity (VA) testing charts at an initial testing distance of 4 meters. A positive change from baseline indicated improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.7","spread":"0.70"},{"groupId":"OG001","value":"1.4","spread":"0.98"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.8","spread":"0.76"},{"groupId":"OG001","value":"2.8","spread":"1.05"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Central Subfield Thickness (CSFT) in Study Eye","description":"CSFT wasassessed by optical coherence tomography (OCT). A negative change from baseline indicates improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-83.6","spread":"127.45"},{"groupId":"OG001","value":"-14.3","spread":"97.36"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-82.5","spread":"140.06"},{"groupId":"OG001","value":"-30.6","spread":"102.77"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-86.5","spread":"136.43"},{"groupId":"OG001","value":"-92.2","spread":"129.85"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-94.5","spread":"141.55"},{"groupId":"OG001","value":"-95.5","spread":"140.68"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-98.6","spread":"136.28"},{"groupId":"OG001","value":"-107.6","spread":"142.22"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-110.6","spread":"133.10"},{"groupId":"OG001","value":"-84.1","spread":"137.86"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-113.3","spread":"130.84"},{"groupId":"OG001","value":"-112.9","spread":"148.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-113.1","spread":"127.11"},{"groupId":"OG001","value":"-107.7","spread":"157.40"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-111.6","spread":"127.99"},{"groupId":"OG001","value":"-116.3","spread":"146.43"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-114.1","spread":"131.12"},{"groupId":"OG001","value":"-116.6","spread":"147.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-112.1","spread":"124.00"},{"groupId":"OG001","value":"-123.5","spread":"140.65"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-121.0","spread":"124.67"},{"groupId":"OG001","value":"-116.8","spread":"137.99"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Central Subfield Volume (CSFV) in Study Eye","description":"CSFV was assessed OCT. A negative change from baseline indicates improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.296","spread":"0.4570"},{"groupId":"OG001","value":"-0.032","spread":"0.3969"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.276","spread":"0.5362"},{"groupId":"OG001","value":"-0.104","spread":"0.3958"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.322","spread":"0.5812"},{"groupId":"OG001","value":"-0.348","spread":"0.5075"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.333","spread":"0.5568"},{"groupId":"OG001","value":"-0.378","spread":"0.5436"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.383","spread":"0.5592"},{"groupId":"OG001","value":"-0.401","spread":"0.5893"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.388","spread":"0.5167"},{"groupId":"OG001","value":"-0.344","spread":"0.5530"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.438","spread":"0.5267"},{"groupId":"OG001","value":"-0.438","spread":"0.6098"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.405","spread":"0.5074"},{"groupId":"OG001","value":"-0.421","spread":"0.6484"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.446","spread":"0.6066"},{"groupId":"OG001","value":"-0.444","spread":"0.6210"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.439","spread":"0.6241"},{"groupId":"OG001","value":"-0.433","spread":"0.6407"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.406","spread":"0.4871"},{"groupId":"OG001","value":"-0.459","spread":"0.6157"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.447","spread":"0.4837"},{"groupId":"OG001","value":"-0.455","spread":"0.5910"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Presence or Absence of Intra-retinal Fluid in Study Eye Compared to Baseline","description":"The presence of intra-retinal fluid was assessed by OCT.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98","spread":null},{"groupId":"OG001","value":"46","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97","spread":null},{"groupId":"OG001","value":"43","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78","spread":null},{"groupId":"OG001","value":"39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Presence or Absence of Subretinal Fluid in Study Eye Compared to Baseline","description":"The presence of subretinal fluid was assessed by OCT.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77","spread":null},{"groupId":"OG001","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75","spread":null},{"groupId":"OG001","value":"35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77","spread":null},{"groupId":"OG001","value":"37","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Presence of Active Macular Edema (ME) Leakage","description":"The presence of active ME leakage was assessed by fluorescein angiography (FA).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96","spread":null},{"groupId":"OG001","value":"53","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Requiring Rescue Treatment at Month 1","description":"Rescue treatment with laser photocoagulation or periocular treatment could be administered at Month 1 only if the participant had a visual acuity loss of \\> 5 letters due to disease activity from baseline to Month 1.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Average Change From Baseline in BCVA","description":"BCVA was assessed in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity (VA) testing charts at an initial testing distance of 4 meters. A positive change from baseline indicated improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.39","spread":"8.405"},{"groupId":"OG001","value":"4.50","spread":"8.095"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.40","spread":"9.052"},{"groupId":"OG001","value":"5.82","spread":"8.927"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With ≥ 1, ≥ 5, ≥ 10 and ≥ 15 Letters Gain or Reaching 84 Letters","description":"VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using ETDRS-like visual acuity testing charts at a testing distance of 4 meters.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80","spread":null},{"groupId":"OG001","value":"38","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null},{"groupId":"OG001","value":"34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87","spread":null},{"groupId":"OG001","value":"40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":null},{"groupId":"OG001","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55","spread":null},{"groupId":"OG001","value":"27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72","spread":null},{"groupId":"OG001","value":"37","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86","spread":null},{"groupId":"OG001","value":"42","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With > 1, > 5, > 10 and > 15 Letters Loss","description":"VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using ETDRS-like visual acuity testing charts at a testing distance of 4 meters.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Ranibizumab Treatments","description":"The number of participants administered study treatments, according to treatment frequency, was assessed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"11","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"11","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Re-treatments","description":"The number of participants, administered re-treatments according to treatment frequency, was assessed. Re-treatment was defined as an administration of study medication following at least one non-missed visit where treatment was not administered in the study eye. Up to Month 12, the maximum number of retreatments was 5.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"15","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Primary Reasons for Decision to Treat by Investigator","description":"The total number of primary reasons for decisions to treat was assessed. A single participant could have had multiple primary reasons for treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"22","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"637","spread":null},{"groupId":"OG001","value":"345","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":15,"n":119},"commonTop":["Conjunctival haemorrhage (Study eye)","Visual acuity reduced (Study eye)","Nasopharyngitis","Eye pain (Study eye)","Macular oedema (Study eye)"]}}}